Arena Pharmaceuticals (NASDAQ:ARNA) Director Donald Belcher sold 1,905 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $6.45, for a total transaction of $12,287.25. Following the completion of the sale, the director now directly owns 68,728 shares of the company’s stock, valued at approximately $443,296. The sale was disclosed in a document filed with the Securities & Exchange Commission. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares after opening at $6.50 moved to $6.59 on last trade day and at the end of the day closed at $6.22. Company price to sales ratio in past twelve months was calculated as 16.75 and price to cash ratio as 6.15. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showed a positive weekly performance of 1.97%.
The EXACT Sciences Corporation (NASDAQ:EXAS) on Apr. 4 announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price of $12.75 per share to the public. The net proceeds to Exact from this offering are expected to be approximately $119.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Exact. The offering is expected to close on or about April 9, 2014, subject to the satisfaction of customary closing conditions. Exact has granted the underwriters a 30-day option to purchase up to an aggregate of 1,500,000 additional shares of common stock. Exact anticipates using the net proceeds from the offering to fund its efforts to obtain FDA approval of its Cologuard test, to fund Cologuard commercialization activities, to fund product development efforts, and for general corporate and working capital purposes. EXACT Sciences Corporation (NASDAQ:EXAS) shares advanced 5.73% in last trading session and ended the day on $13.66. EXAS return on equity ratio is recorded as -35.60% and its return on assets is -33.00%. EXACT Sciences Corporation (NASDAQ:EXAS) yearly performance is 36.74%.
MannKind Corporation (NASDAQ:MNKD)revealed Tuesday that the Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee had given a vote of confidence to MannKind’s diabetes drug Afrezza. The 14-person committee voted 13-1 in favor of approval for the drug. The news, which was revealed after the market closed, pushed the stock up as much as 130% in after-hours. MannKind stock had closed up 73.88% at the close of trading yesterday, and is currently up about 4% pre-market. MannKind Corporation (NASDAQ:MNKD) shares moved down -0.87% in last trading session and was closed at $6.87, while trading in range of $6.70-$7.01. MannKind Corporation (NASDAQ:MNKD) year to date performance is 32.12%.
Ariad Pharmaceuticals (NASDAQ:ARIA) SVP Maria Cantor unloaded 4,250 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $8.21, for a total transaction of $34,892.50. Following the transaction, the senior vice president now directly owns 88,174 shares in the company, valued at approximately $723,909. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is -5.01%. On last trading day company shares ended up $7.58. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average is -6.34%. Analysts mean target price for the company is $9.06.
Leave a Reply